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Abstract
Background The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-
blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia 
gravis (gMG), and its open-label extension.
Methods Attainment of ‘minimal symptom expression’ was evaluated using patient-reported outcome measures of gMG 
symptoms [MG activities of daily living scale (MG-ADL), 15-item MG quality of life questionnaire (MG-QOL15)] at the 
completion of REGAIN and during the open-label extension. ‘Minimal symptom expression’ was defined as MG-ADL total 
score of 0–1 or MG-QOL15 total score of 0–3.
Results At REGAIN week 26, more eculizumab-treated patients achieved ‘minimal symptom expression’ versus placebo 
[MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 
1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069]. During the open-label extension, the proportion of patients in the 
placebo/eculizumab group who achieved ‘minimal symptom expression’ increased after initiating eculizumab treatment 
and was sustained through 130 weeks of open-label eculizumab (MG-ADL: 1.7 to 27.8%; MG-QOL15: 1.7 to 19.4%). At 
extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups 
achieved ‘minimal symptom expression’ (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 
19.4%, respectively, p = 0.7531). The long-term tolerability of eculizumab was consistent with previous reports.
Conclusions Patients with AChR+ refractory gMG who receive eculizumab can achieve sustained ‘minimal symptom 
expression’ based on patient-reported outcomes. ‘Minimal symptom expression’ may be a useful tool in measuring therapy 
effectiveness in gMG.
Trial registration ClinicalTrials.gov NCT01997229, NCT02301624.
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Introduction
Generalized myasthenia gravis (gMG) is an autoimmune 
disorder characterized by muscle weakness that worsens 
with muscle use [1, 2]. Symptoms associated with gMG 
include muscle weakness resulting in dysarthria, dyspha-
gia, dyspnoea and fatigue in the muscles of the face, neck, 
arms, hands and legs [3]. Although there is no generally 
recognized standard definition of ‘refractory’ disease in 
gMG, criteria for refractory disease that have been used 
include failure to respond to conventional treatments such 
as immunosuppressive therapies (ISTs), inability to reduce 
IST use without clinical relapse, intolerable adverse reac-
tions to conventional treatments, requirement for large 
doses of potentially harmful agents such as ISTs, pres-
ence of comorbidities that contraindicate conventional 
treatments, requirement for repeated short-term rescue 
therapy (e.g. intravenous immunoglobulin and plasma 
exchange) and recurrent myasthenic crises [1, 4–7]. As 
a consequence of their continued disease symptoms and 
persistent morbidities, patients with refractory gMG expe-
rience a heavy clinical burden [4], which severely impairs 
their quality of life (QOL) [8].
More than 70% of patients with gMG produce autoan-
tibodies directed against acetylcholine receptor (AChR); 
these patients are classed as being AChR+ . The presence 
of these antibodies leads to reduced binding of the neuro-
transmitter acetylcholine to its receptor, accelerated deg-
radation of AChRs and activation of the complement cas-
cade [9–11]. Complement activation results in the cleavage 
of the terminal complement protein C5 into C5a and C5b 
by the C5 convertase enzyme complexes, thus activating 
the terminal complement cascade [12]. The combination 
of accelerated AChR degradation and the complement 
cascade results in structural damage to the neuromuscular 
junction, contributing to impaired neurotransmission and 
the muscle weakness characteristic of gMG [9].
The humanized monoclonal antibody eculizumab 
specifically binds to and inhibits cleavage of C5 [12]. 
The phase 3, randomized, placebo-controlled REGAIN 
study demonstrated the efficacy and tolerability of ecu-
lizumab in AChR+ refractory gMG during 6 months of 
therapy (NCT01997229) [13]. An interim analysis of the 
open-label extension of REGAIN found that eculizumab 
remained effective and well tolerated for up to 3 years of 
extended treatment (NCT02301624) [14]. During these 
studies, key efficacy endpoint assessments included the 
patient-reported MG activities of daily living scale (MG-
ADL) [15] and the 15-item MG quality of life question-
naire (MG-QOL15) [16].
Current definitions of minimal symptoms in MG rely on 
physician evaluation. There are currently no definitions of 
minimal symptoms based exclusively on patients’ assess-
ments of their symptoms and QOL; this type of measure-
ment could potentially be more meaningful for patients 
than physician-based evaluations. In a validation study for 
the MG-QOL15, patients in remission had a mean MG-
QOL15 total score of 3.3 (standard deviation, 4.4), with a 
range of 0–15 [17]. Remission was defined as an MG com-
posite score of 0 and a score of 0 on either the MG-ADL 
or the MG manual muscle test, with the exception that an 
eye closure score of 1 (mild weakness) was permitted [17].
For this analysis, we adapted this previous definition of 
remission [17] to develop the concept of ‘minimal symp-
tom expression’, using the patient-reported measures of MG-
ADL and MG-QOL15 that were used in REGAIN and the 
open-label extension study. This is the first analysis of its 
kind to use ‘minimal symptom expression’ as an efficacy 
endpoint in gMG.
Methods
Study design and participants
The efficacy and tolerability of eculizumab were assessed 
in a 6-month (26-week), phase 3, randomized, placebo-
controlled study of patients with AChR+ refractory gMG 
aged 18 years or older (REGAIN) [13]. The first patient 
was enrolled on 30 April 2014. Eligible patients had con-
firmed AChR+ gMG; had an MG-ADL total score of at 
least 6; and had received at least two ISTs, or at least one 
IST with intravenous immunoglobulin or plasma exchange 
treatment at least four times in 12 months without symptom 
control. Exclusion criteria included ocular-only MG symp-
toms [Myasthenia Gravis Foundation of America (MGFA) 
class I] or myasthenic crisis at screening (MGFA class V). 
Full eligibility criteria have been published previously [13]. 
Patients could enrol in the open-label extension study in the 
2 weeks after completing REGAIN to receive open-label 
eculizumab for up to a maximum of 4 years. The extension 
study was completed in January 2019 [14].
At least 2 weeks before starting study treatment, patients 
were vaccinated against Neisseria meningitidis. Patients who 
were not vaccinated at the appropriate time received pro-
phylactic antibiotics until 2 weeks after vaccination. During 
the open-label extension study, when appropriate accord-
ing to local guidelines, patients were revaccinated against 
N. meningitidis. During REGAIN, patients who previously 
received ISTs were required to maintain their pre-study dose 
and schedule. During the open-label extension of REGAIN, 
modifications to IST dose and schedule were permitted at 
the study investigator’s discretion.
All patients provided written, informed consent. Inde-
pendent ethics committees or institutional review boards 
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provided written approval for the study protocols and all 
amendments. The studies are registered at www.clini caltr 
ials.gov.
Study treatment dosing and scheduling
During REGAIN, patients randomized to eculizumab 
received an induction dose of 900 mg of eculizumab on day 
1 and at weeks 1, 2 and 3, followed by a maintenance dose of 
1200 mg of eculizumab at week 4 and every 2 weeks there-
after [13]. Placebo was administered using the same sched-
ule. All patients who continued into the open-label extension 
study from REGAIN underwent a 4-week blinded induction 
phase. During this phase, patients who had received eculi-
zumab during REGAIN received eculizumab 1200 mg on 
day 1 and at week 2, and placebo at weeks 1 and 3 (eculi-
zumab/eculizumab group). Patients who had received pla-
cebo during REGAIN received eculizumab 900 mg on day 
1 and at weeks 1, 2 and 3 (placebo/eculizumab group). All 
patients received open-label eculizumab 1200 mg at week 4 
and every 2 weeks thereafter.
Assessments
The objective of REGAIN and the open-label extension 
study was to assess the tolerability of eculizumab and its 
efficacy, as measured by change in MG-ADL total score 
from each study’s baseline. This sub-analysis evaluated 
the achievement of ‘minimal symptom expression’ in both 
studies, defined as achievement of an MG-ADL total score 
of 0–1 (range 0–24) or an MG-QOL15 total score of 0–3 
(range 0–60).
The proportions of patients achieving ‘minimal symptom 
expression’ were calculated for the eculizumab and placebo 
treatment groups at week 26 of REGAIN and up to week 
130 of the open-label extension (a total of 156 weeks of 
eculizumab treatment for the eculizumab/eculizumab group 
and 130 weeks of eculizumab treatment for the placebo/
eculizumab group). Achievement of a clinically meaningful 
quantitative MG (QMG) response, defined as an improve-
ment of at least 5 points in QMG total score, during the 
study was also recorded.
Adverse events were reported and coded by preferred 
term using the Medical Dictionary for Regulatory Activities 
version 20.1. MG exacerbations, rescue therapy use and dis-
continuations because of adverse events were also recorded.
Statistical analysis
The significance of differences between groups was evalu-
ated by calculating p values based on Fisher’s exact test for 
categorical variables and a two-sample t-test for continuous 
variables.
Results
Patient demographics and characteristics
Data are reported from the REGAIN study and its open-
label extension for up to a maximum total of 156 weeks of 
eculizumab treatment. Of the 118 patients who completed 
REGAIN, 117 patients continued into the open-label study 
(eculizumab/eculizumab n = 56, placebo/eculizumab n = 61; 
Fig. 1) and were included in the efficacy and safety analyses. 
Patient demographics and characteristics were similar for 
the eculizumab/eculizumab and placebo/eculizumab groups, 
with the exception that there was a greater proportion of 
Asian patients in the placebo/eculizumab group (Table 1).
Fig. 1  Patient disposition in 
REGAIN and the open-label 
study
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‘Minimal symptom expression’ status during REGAIN
At week 26 of REGAIN, a significantly higher proportion 
of patients receiving eculizumab achieved ‘minimal symp-
tom expression’ than of those receiving placebo according 
to MG-ADL score (21.4% and 1.7%, respectively; difference 
19.8%; 95% confidence interval [CI] 8.5, 31.0; p = 0.0007; 
Fig. 2a) and MG-QOL15 score (16.1% and 1.7%, respec-
tively; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069; 
Fig. 2b).
‘Minimal symptom expression’ status 
during the open‑label study
During the open-label extension, the proportion of patients 
in the eculizumab/eculizumab group with ‘minimal symp-
tom expression’ was maintained for 2.5 years, between 
REGAIN week 26 and open-label week 130 (MG-ADL: 
21.4% and 22.9%, respectively; MG-QOL15: 16.1% and 
14.3%, respectively). In the placebo/eculizumab group, 
the proportion of patients with ‘minimal symptom expres-
sion’ increased to levels similar to those in the eculizumab/
eculizumab group in the 4 weeks after starting open-label 
eculizumab therapy, between REGAIN week 26 and open-
label week 4 (MG-ADL: 1.7% and 21.3%, respectively; 
MG-QOL15: 1.7% and 17.2%, respectively). This increase 
was sustained to open-label week 130 (MG-ADL: 27.8%; 
MG-QOL15: 19.4%).
At week 130 of the open-label extension, ‘minimal 
symptom expression’ was achieved by similar proportions 
of patients in the eculizumab/eculizumab and placebo/ecu-
lizumab groups as assessed by MG-ADL score (22.9% and 
27.8%, respectively; difference −4.9%; 95% CI −25.1, 15.3; 
p = 0.7861; Fig. 2a). The proportions of patients achieving 
‘minimal symptom expression’ at week 130 based on MG-
QOL15 score were also similar in the two groups, being 
14.3% in the eculizumab/eculizumab group and 19.4% in 
the placebo/eculizumab group (difference −5.2%; 95% 
CI −22.5, 12.2; p = 0.7531; Fig. 2b). Overall, 25.4% of ecu-
lizumab-treated patients experienced ‘minimal symptom 
expression’ according to MG-ADL and 16.9% according to 
MG-QOL15 at this time point.
Most eculizumab-treated patients who achieved ‘minimal 
symptom expression’ at any time also experienced a clini-
cally meaningful improvement in physician-reported QMG 
total score, defined as an improvement of at least 5 points 
from eculizumab start. For ‘minimal symptom expres-
sion’ according to MG-ADL total score, this proportion 
was 85.7% (42/49) and, for ‘minimal symptom expression’ 
according to MG-QOL15 total score, it was 81.1% (30/37).
There was no significant difference in mean age at first 
eculizumab dose between eculizumab-treated patients 
who achieved ‘minimal symptom expression’ accord-
ing to MG-ADL at any time during REGAIN and the 
open-label study (up to week 130) and those who did 
not (47.4 vs 47.0 years; p = 0.8847). Mean disease dura-
tion at first eculizumab dose was shorter for patients 
who achieved ‘minimal symptom expression’ according 
to MG-ADL by open-label week 130 than for those who 
did not [8.27 (range 1.6–27.0) vs 11.16 (range 1.7–34.4) 
years; p = 0.0474]. For achievement of ‘minimal symp-
tom expression’ according to MG-QOL15 up to open-
label week 130, there were no significant differences in 
mean age (44.6 vs 48.4 years; p = 0.2611) or mean disease 
Table 1  Demographics and 
characteristics at REGAIN 
baseline of patients who 
continued from REGAIN into 
the open-label extension study
MG myasthenia gravis, MG-ADL myasthenia gravis activities of daily living questionnaire, MG-QOL15 
15-item myasthenia gravis quality of life questionnaire, SD standard deviation
a At first dose in REGAIN
b Time from MG diagnosis to date of first dose in REGAIN
Variable Eculizumab/ecu-
lizumab n = 56
Placebo/eculi-
zumab n = 61
All patients N = 117
Age,  yearsa, mean (SD) 46.8 (15.6) 47.0 (17.8) 46.9 (16.7)
Sex, n (%)
 Male 18 (32.1) 20 (32.8) 38 (32.5)
 Female 38 (67.9) 41 (67.2) 79 (67.5)
Race, n (%)
 Asian 3 (5.4) 16 (26.2) 19 (16.2)
 Black or African-American 0 (0.0) 2 (3.3) 2 (1.7)
 White 47 (83.9) 41 (67.2) 88 (75.2)
 Other/multiple/unknown 6 (10.7) 2 (3.3) 8 (6.8)
Duration of  MGb, years, mean (SD) 10.2 (7.9) 9.2 (8.6) 9.7 (8.2)
Baseline MG-ADL total score, mean (SD) 10.3 (3.0) 9.9 (2.6) 10.1 (2.8)
Baseline MG-QOL15 total score, mean (SD) 32.5 (12.0) 30.8 (12.9) 31.6 (12.5)
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duration at first eculizumab dose [8.73 (range 1.6–24.6) vs 
10.51 (range 1.7–34.4) years; p = 0.2091]. No significant 
differences were found between patients who did and did 
not achieve ‘minimal symptom expression’, according to 
either MG-ADL or MG-QOL15 scores, in other baseline 
characteristics, including sex, race, MGFA class, history 
of MG crisis and history of IST use. The only significant 
differences in baseline MG-ADL, MG-QOL15 and QMG 
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Fig. 2  a Proportions of patients achieving ‘minimal symptom expres-
sion’, defined as an MG-ADL total score of 0–1. b Proportions of 
patients achieving ‘minimal symptom expression’, defined as an MG-
QOL15 total score of 0–3. *p < 0.01; **p < 0.001 vs placebo. p values 
are based on Fisher’s exact test. MG-ADL myasthenia gravis activities 
of daily living questionnaire, MG-QOL15 15-item myasthenia gravis 
quality of life questionnaire
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total scores were for MG-ADL (p = 0.0380) and MG-
QOL15 (p = 0.0487) between patients who did achieve 
‘minimal symptom expression’ according to MG-QOL15 
and those who did not (Table 2).
The mean MG-ADL total score for the open-label 
study population decreased from 10.1 [standard deviation 
(SD) 2.80; n = 117] at REGAIN baseline to 3.9 (SD 3.08; 
n = 71) at open-label week 130. The mean MG-QOL15 
total score also reduced between these time points, from 
31.6 (SD 12.48) to 15.3 (SD 12.15).
Safety
Safety data have previously been published for REGAIN and 
an interim analysis of the open-label extension study [13, 
14]. During these two studies, headache and nasopharyn-
gitis were the most common adverse events among patients 
receiving eculizumab (experienced by 44.4% and 38.5%, 
respectively, from REGAIN baseline to week 130 of the 
open-label extension). MG worsening was experienced by 
15.4% of eculizumab-treated patients, MG crisis by 3.4% 
Table 2  Baseline demographics and characteristics of patients who did or did not achieve ‘minimal symptom expression’ at any time during 
REGAIN and the open-label extension study
IST immunosuppressive therapy, MG myasthenia gravis, MG-ADL myasthenia gravis activities of daily living scale, MGFA Myasthenia Gravis 
Foundation of America, MG-QOL15 15-item myasthenia gravis quality of life questionnaire, QMG quantitative myasthenia gravis scale, SD 
standard deviation
a The significance of differences between groups was evaluated by calculating p values based on Fisher’s exact test for categorical variables and 
a two-sample t-test for continuous variables
b Time from MG diagnosis to date of first eculizumab dose
Variable MG-ADL total score 0–1 MG-QOL15 total score 0–3
Did achieve n = 49 Did not achieve n = 68 p  valuea Did achieve n = 37 Did not achieve n = 80 p  valuea
Sex, n (%)
 Male 14 (28.6) 24 (35.3) 0.5491 11 (29.7) 27 (33.8) 0.8322
 Female 35 (71.4) 44 (64.7) 26 (70.3) 53 (66.3)
Race, n (%)
 Asian 7 (14.3) 12 (17.6) 0.5767 5 (13.5) 14 (17.5) 0.3377
 Black or African American 1 (2.0) 1 (1.5) 1 (2.7) 1 (1.3)
 White 39 (79.6) 49 (72.1) 28 (75.7) 60 (75.0)
 Other/multiple/unknown 2 (4.1) 6 (8.8) 3 (8.1) 5 (6.3)
Age at first eculizumab dose, years, 
mean (SD)
47.4 (18.79) 47.0 (15.25) 0.8847 44.6 (19.23) 48.4 (15.45) 0.2611
Duration of MG at first eculizumab 
 doseb, years, mean (SD)
8.3 (6.57) 11.2 (9.08) 0.0474 8.7 (5.97) 10.5 (9.05) 0.2091
MG-ADL total score at REGAIN 
baseline, mean (SD)
9.6 (3.08) 10.4 (2.55) 0.1061 9.3 (2.79) 10.5 (2.75) 0.0380
MG-QOL15 total score at REGAIN 
baseline, mean (SD)
31.0 (13.23) 32.0 (12.00) 0.6709 28.2 (14.14) 33.1 (11.40) 0.0487
QMG total score at REGAIN base-
line, mean (SD)
16.8 (5.51) 17.1 (5.21) 0.8247 17.1 (5.77) 16.9 (5.13) 0.9034
Patients with MGFA class at REGAIN screening, n (%)
 IIa 10 (20.4) 14 (20.6) 0.7087 10 (27.0) 14 (17.5) 0.7954
 IIb 11 (22.4) 8 (11.8) 7 (18.9) 12 (15.0)
 IIIa 13 (26.5) 21 (30.9) 10 (27.0) 24 (30.0)
 IIIb 10 (20.4) 18 (26.5) 8 (21.6) 20 (25.0)
 IVa 2 (4.1) 4 (5.9) 1 (2.7) 5 (6.3)
 IVb 3 (6.1) 3 (4.4) 1 (2.7) 5 (6.3)
Patients with history of MG crisis 
before REGAIN, n (%)
8 (16.3) 13 (19.1) 0.8091 6 (16.2) 15 (18.8) 0.8018
Patients using ISTs before REGAIN, n (%)
 1 IST 0 (0.0) 2 (2.9) 0.1818 0 (0.0) 2 (2.5) 0.0520
 2 ISTs 27 (55.1) 26 (38.2) 22 (59.5) 31 (38.8)
 3 ISTs 15 (30.6) 23 (33.8) 12 (32.4) 26 (32.5)
 ≥ 4 ISTs 7 (14.3) 17 (25.0) 3 (8.1) 21 (26.3)
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and MG exacerbations by 29.1%. A total of 11 patients dis-
continued eculizumab therapy owing to adverse events dur-
ing the two studies. One patient contracted a meningococ-
cal infection, which was resolved with antibiotic treatment 
[13]. Three deaths were reported in patients with important 
comorbidities that were likely to have contributed to the 
clinical outcome [13].
Discussion
This analysis found that, at the end of REGAIN, a signifi-
cantly greater proportion of patients with AChR+ refractory 
gMG treated with eculizumab experienced ‘minimal symp-
tom expression’ than of those receiving placebo according to 
an MG-ADL total score of 0–1 or an MG-QOL15 total score 
of 0–3. The proportions of patients experiencing ‘minimal 
symptom expression’ were maintained through 2.5 years of 
open-label eculizumab therapy in the extension study.
The only significant difference in baseline characteris-
tics between patients who did and did not achieve ‘minimal 
symptom expression’ according to MG-ADL was in disease 
duration, and the only significant differences in the achieve-
ment of ‘minimal symptom expression’ according to MG-
QOL15 were in MG-ADL and MG-QOL15 total scores at 
REGAIN baseline. The difference in baseline MG-ADL 
total score between these groups was small (1.2) and not 
clinically relevant. The baseline MG-QOL15 score was 4.9 
points lower in patients who did achieve ‘minimal symptom 
expression’ according to MG-QOL15 than in those who did 
not, which may simply reflect that less improvement was 
required for patients with a lower baseline MG-QOL15 score 
to achieve a score of 3 or less. Overall, patients who did 
achieve ‘minimal symptom expression’ did not have less 
severe disease before eculizumab treatment than those who 
did not achieve it.
It is notable that, among a group of patients with refrac-
tory gMG with a mean MG-ADL total score of 10.1 at the 
start of REGAIN, approximately a quarter reported ‘minimal 
symptom expression’ defined as an MG-ADL total score of 
0–1 through week 130 of the open-label study, by which 
time point the mean MG-ADL total score had reduced by 
more than half to 3.9. This reflects patient-reported improve-
ments in disease burden in excess of the two-point reduction 
in MG-ADL total score that is considered to be a clinically 
meaningful improvement [18] to a level that has previously 
been described as disease remission [17]. In addition, ‘mini-
mal symptom expression’, defined as an MG-QOL15 total 
score of 0–3, was achieved by one-sixth of these patients, 
and the mean MG-QOL15 total score halved between the 
start of REGAIN (31.6) and week 130 of the open-label 
study (15.3). The smaller proportion achieving ‘minimal 
symptom expression’ according to MG-QOL15 versus 
MG-ADL (one-sixth vs one-quarter) may be due to the con-
servative MG-QOL15 total score range (0–3) used in the 
definition of ‘minimal symptom expression’ in this analysis.
A correlation between changes in patient-reported MG-
ADL scores and physician-assessed QMG scores has been 
described previously [19, 20]. In REGAIN and its open-label 
extension, patient-reported improvements were reflected in 
improvements in physician-reported outcomes assessed 
using QMG scoring. Almost half of eculizumab-treated 
patients achieved a clinically meaningful improvement in 
QMG total score (a reduction of at least 5 points) in the 
26 weeks of REGAIN, and significant decreases in mean 
QMG total scores with eculizumab were maintained for up 
to 3 years during REGAIN and its open-label extension [13, 
14]. In this analysis, most patients who achieved patient-
reported ‘minimal symptom expression’ also achieved a 
clinically meaningful physician-reported QMG response.
The long-term tolerability of eculizumab was consistent 
with its known adverse event profile from established indica-
tions [21–25], and no new safety signals were observed since 
the interim analysis of the open-label extension study [14].
The main limitation of this post hoc analysis is the open-
label design of the extension study, which could yield uncon-
scious bias in reporting. Given that over 90% of patients who 
enrolled in REGAIN continued into the open-label study, 
selection bias in the open-label study population is unlikely. 
Further, the novel definition of ‘minimal symptom expres-
sion’ used in this analysis was derived from previous defini-
tions of remission and has not yet been formally validated. 
In addition, further research is needed to evaluate the opti-
mal range for this patient-reported assessment because this 
analysis used a conservative MG-QOL15 total score range 
of 0–3 to indicate ‘minimal symptom expression’.
In conclusion, the results of this analysis confirm a rapid 
and sustained clinical response to eculizumab in patients 
with refractory gMG, reflected in the higher proportion 
reporting ‘minimal symptom expression’ with eculizumab 
than with placebo. Despite having refractory MG, individu-
als can achieve long-term ‘minimal symptom expression’ 
with eculizumab therapy. The current lack of validated defi-
nitions of minimal symptoms based exclusively on patients’ 
assessments of their symptoms and QOL makes it difficult to 
comment on the generalizability of these findings. However, 
this type of assessment could potentially be more meaning-
ful for patients than physician-based evaluations. ‘Minimal 
symptom expression’ based on quantitative, patient-reported 
outcomes may, therefore, be a useful tool in measuring 
patient progress following therapeutic intervention.
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